Equities Analysts Offer Predictions for REGN FY2025 Earnings

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Equities researchers at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Regeneron Pharmaceuticals in a research report issued to clients and investors on Tuesday, April 22nd. Cantor Fitzgerald analyst C. Gould anticipates that the biopharmaceutical company will post earnings of $26.38 per share for the year. Cantor Fitzgerald currently has a “Overweight” rating and a $695.00 target price on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.79 billion during the quarter, compared to the consensus estimate of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% compared to the same quarter last year.

REGN has been the subject of several other reports. Sanford C. Bernstein decreased their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Bank of America lowered their target price on shares of Regeneron Pharmaceuticals from $575.00 to $547.00 and set an “underperform” rating for the company in a research note on Thursday, April 17th. The Goldman Sachs Group decreased their price objective on Regeneron Pharmaceuticals from $1,019.00 to $917.00 and set a “buy” rating for the company in a report on Monday, April 14th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Tuesday. Finally, Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $945.32.

Regeneron Pharmaceuticals Trading Up 0.5 %

Shares of NASDAQ REGN opened at $602.64 on Thursday. Regeneron Pharmaceuticals has a 1-year low of $525.99 and a 1-year high of $1,211.20. The business has a fifty day moving average price of $637.38 and a 200 day moving average price of $725.82. The stock has a market capitalization of $65.88 billion, a P/E ratio of 15.74, a price-to-earnings-growth ratio of 2.34 and a beta of 0.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were given a $0.88 dividend. The ex-dividend date of this dividend was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 2.30%.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Mather Group LLC. boosted its position in Regeneron Pharmaceuticals by 20.2% during the first quarter. Mather Group LLC. now owns 1,090 shares of the biopharmaceutical company’s stock worth $691,000 after purchasing an additional 183 shares in the last quarter. Alta Advisers Ltd lifted its position in shares of Regeneron Pharmaceuticals by 70.0% during the 1st quarter. Alta Advisers Ltd now owns 607 shares of the biopharmaceutical company’s stock valued at $385,000 after buying an additional 250 shares in the last quarter. RedJay Asset Management Inc. purchased a new stake in Regeneron Pharmaceuticals in the 1st quarter worth $1,268,000. Valley National Advisers Inc. raised its position in Regeneron Pharmaceuticals by 10.7% during the first quarter. Valley National Advisers Inc. now owns 1,371 shares of the biopharmaceutical company’s stock worth $869,000 after acquiring an additional 132 shares during the period. Finally, Washington Trust Advisors Inc. lifted its holdings in Regeneron Pharmaceuticals by 0.8% during the first quarter. Washington Trust Advisors Inc. now owns 29,526 shares of the biopharmaceutical company’s stock valued at $18,726,000 after purchasing an additional 236 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.